Drugmakers showed their appetite for orphan-disease drugs Monday, with two billion-dollar-plus deals sending stocks soaring. Israeli drug giant Teva Pharmaceutical Industries (TEVA) agreed to pay $101 a share in cash for Auspex Pharmaceuticals (ASPX), a development-stage biotech that plans to apply for approval of its Huntington’s disease treatment in the next few months. The company is also developing treatments for other central-nervous-system
Israeli drug giant Teva Pharmaceutical Industries (TEVA) reported successful midstage trial results for its novel migraine treatment and appointed a new head of business development Monday, sending its stock to a five-year high above 63. Teva reported results for a phase 2b study of TEV-48125, an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody treating episodic migraines. The trial met its endpoint of a statistically significant
Going into Thursday trading, Mylan (MYL) stock stands a chance of entering buy range. Shares closed up 6.7% Wednesday at 59, briefly rising past a buy point of 59.70 during the day, after product launches and chatter about whether it could be for sale, maybe to Teva Pharmaceutical Industries (TEVA). Mylan stock opened at 59.07 Thursday morning and was trading at 59.55 early on. Mylan is among top-rated stocks in the generic drugs industry, along